Researchers at SVI have discovered that a drug called baricitinib may help people who have type 1 diabetes to produce insulin for longer after diagnosis.
The drug is expected to stop the immune system from attacking the insulin-producing cells in the pancreas. This type of treatment – harnessing the immune system to treat disease – is called immunotherapy.
Baricitinib is approved around the world for patients with rheumatoid arthritis. In a global first, the BANDIT (Baricitinib in new onset type 1 diabetes) trial will test baricitinib’s effectiveness for people recently diagnosed with type 1 diabetes.
The BANDIT trial is supported by JDRF Australia and JDRF International.
Thanks to the generosity of the type 1 diabetes community, we have finished recruiting participants for the BANDIT trial, and have begun analysing the data collected.
We hope to begin sharing information about the findings of the BANDIT trial in the next 6 to 12 months.BANDIT study team
Professor Tom Kay
Professor Helen Thomas
Associate Professor John Wentworth
Lead Clinician (The Royal Melbourne Hospital)
Professor Fergus Cameron
Site Leader (The Royal Children’s Hospital Melbourne)
Professor Jenny Couper
Site Leader (Adelaide Women’s and Children’s Hospital)
Associate Professor Balasubramanian Krishnamurthy
Senior clinician researcher
Professor Richard MacIsaac
Site Lead (St Vincent’s Hospital Melbourne)
Professor Peter Colman
Dr Michaela Waibel
Project ManagerOther type 1 diabetes clinical trials
SVI leads the Australasian Type 1 Diabetes Collaborative (ATIC) and will be involved in future immunotherapy clinical trials for people with type 1 diabetes. To express your interest to participate in future type 1 diabetes immunotherapy trials, please get in touch.
To find out about other clinical trial opportunities in Australia, visit:
- JDRF Australia
- Australian Clinical TrialsTo find out about other type 1 diabetes clinical trial opportunities happening globally, visit:
Each clinical trial will have its own specific eligibility guidelines. We recommend you contact the trial managers or clinical trial site personnel for more information on specific trials.Other SVI type 1 diabetes programs and facilities